Torrent Pharma Expands Gastrointestinal Portfolio with Launch of Kabvie for GERD Treatment

Torrent Pharmaceuticals Limited (Torrent), a leading player in the Indian pharmaceutical industry, announced a strategic move to match the growing burden of Gastroesophageal Reflux Disease (GERD) in the country. Torrent Pharmaceuticals has entered into a non-exclusive patent licensing agreement with Takeda Pharmaceuticals to commercialise Vonoprazan, a novel potassium-competitive acid blocker (P-CAB), in India. Torrent will market Vonoprazan under its own brand name, Kabvie.

GERD is a common digestive disorder characterized by frequent heartburn and acid reflux. Statistics from a 2019 study published in the Indian Journal of Gastroenterology reveal a national prevalence of GERD around 8.2%, with an even higher incidence of 11.1% in urban areas. This condition significantly impacts quality of life and can lead to further complications if left untreated.

A New Treatment Option

The Indian market for GERD treatments presents a significant opportunity, valued at ₹8,064 crore, according to AWACS MAT data for April 2024. This market has witnessed a steady growth rate of 8% CAGR over the past four years. Traditionally, Proton Pump Inhibitors (PPIs) have been the mainstay of GERD treatment. The introduction of P-CABs like Kabvie offers patients a new and potentially more effective treatment option.

Broadening Treatment Accessibility

Torrent’s partnership with Takeda ensures broader accessibility of this innovative P-CAB therapy. By marketing Kabvie, Torrent aims to make this treatment more readily available to the Indian population, empowering healthcare providers with a wider range of options for managing GERD effectively.

“We are delighted to commercialise this novel treatment for Indian patients. I am confident that the launch of Kabvie will aid in reducing the disease burden of GERD and further strengthen our Gastrointestinal offerings, augmenting our position as a leading player within the Indian Pharmaceutical Market,” said Aman Mehta, Director of Torrent.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.